Skip to main content

Table 1 Participant summary characteristics

From: Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease

CharacteristicAll (n = 85)No DKD (n = 42)DKD (n = 43)P value
Mean Baseline eGFR (ml/min/1.73 m2, SD)75.0 ± 21.483.8 ± 13.366.5 ± 24.4< 0.01
Mean Baseline ACR (mg/mmol, SD)17.9 ± 62.11.0 ± 0.6734.4 ± 84.60.01
Male, n (%)50 (58.8)24 (57.1)26 (60.5)0.76
Age at 1st injection (years, SD)64.4 ± 9.462.9 ± 7.765.8 ± 10.60.16
Type 2 Diabetes mellitus, n (%)66 (77.6)30 (71.4)36 (83.7)0.17
Mean Duration of diabetes (years, SD)16.5 ± 11.416.2 ± 12.416.7 ± 10.60.85
Mean HbA1c (mmol/mol, SD)67.3 ± 16.165.7 ± 13.168.9 ± 18.50.36
Hypertension, n (%)71 (83.5)30 (71.4)41 (95.3)< 0.01
Hyperlipidaemia, n (%)65 (76.5)31 (73.8)34 (79.1)0.57
Coronary Heart Disease or Heart Failure, n (%)31 (36.5)11 (26.2)20 (46.5)0.05
Cerebrovascular Disease, n (%)12 (14.1)2 (4.8)10 (23.3)0.03
Never smoked, n (%)53 (62.4)28 (66.6)25 (58.1)0.04
Angiotensin Converting Enzyme Inhibitor, n (%)41 (48.2)19 (45.2)22 (51.2)0.59
Angiotensin Receptor Antagonist, n (%)14 (16.5)6 (14.3)8 (18.6)0.59
Calcium Channel Blocker, n (%)34 (40.0)12 (28.6)22 (51.2)0.03
Thiazide Diuretic, n (%)7 (8.2)2 (4.8)5 (11.6)0.43
Spironolactone, n (%)3 (3.5)0 (0.0)3 (7.0)0.24
Loop Diuretic, n (%)13 (15.3)1 (2.4)12 (27.9)< 0.01
Beta Blocker, n (%)26 (30.6)8 (19.0)18 (41.9)0.02
Statin, n (%)68 (80.0)32 (76.2)36 (83.7)0.39
Metformin, n (%)53 (62.4)24 (57.1)29 (67.4)0.33
Aspirin, n (%)39 (45.9)20 (47.6)19 (44.2)0.75
Alpha Blockers, n (%)11 (12.9)4 (9.5)7 (16.3)0.52
Clopidogrel, n (%)
Proton Pump Inhibitor, n (%)
12 (14.1)
24 (28.2)
7 (16.6)
10 (23.9)
5 (11.6)
14 (32.6)
0.51
0.37
  1. Values provided are n (%) for categorical variables and mean ± SD for continuous variables
  2. Abbreviations: DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; ACR, albumin-to-creatinine ratio; HbA1c, glycated haemoglobin; SD, standard deviation